PMID- 21186969
OWN - NLM
STAT- MEDLINE
DCOM- 20110411
LR  - 20211020
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 20
IP  - 6
DP  - 2010 Dec
TI  - Executive function deficits in children with attention-deficit/hyperactivity 
      disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
PG  - 503-11
LID - 10.1089/cap.2009.0110 [doi]
AB  - OBJECTIVE: To assess the effects of lisdexamfetamine dimesylate (LDX) on 
      executive function (EF) behaviors in children with 
      attention-deficit/hyperactivity disorder (ADHD). METHODS: This observational, 
      open-label, 7-week, dose-optimization study of LDX (20-70  mg/day) in children 
      with ADHD evaluated efficacy with the ADHD Rating Scale IV; safety measures 
      included adverse events (AEs). EF was assessed with the Behavior Rating Inventory 
      of Executive Function (BRIEF). Post hoc analyses examined BRIEF scores by sex, 
      ADHD subtype, comorbid psychiatric symptoms, and common treatment-emergent AEs 
      (TEAEs). ADHD Rating Scale IV scores were assessed in subjects categorized by 
      baseline BRIEF global executive composite T scores with clinically significant 
      (>/=65) or not clinically significant (<65) impairment in EF. RESULTS: Mean 
      (standard deviation) change from baseline to endpoint for BRIEF of -17.9 (12.5) 
      for Global Executive Composite, -15.4 (12.6) for Behavioral Regulation Index, and 
      -17.6 (12.3) for Metacognition Index demonstrated improvement with LDX (pooled 
      doses; p < 0.0001 for all). Improvements in BRIEF scores were seen regardless of 
      sex, ADHD subtype, comorbid psychiatric symptoms, common TEAEs, or baseline EF 
      impairment category. TEAEs included decreased appetite, decreased weight, 
      irritability, insomnia, headache, upper abdominal pain, and initial insomnia. 
      CONCLUSIONS: Improvements were demonstrated in EF behaviors and ADHD symptoms 
      with LDX. LDX safety profile was consistent with long-acting stimulant use.
FAU - Turgay, Atilla
AU  - Turgay A
AD  - University of Toronto, Toronto, Canada.
FAU - Ginsberg, Lawrence
AU  - Ginsberg L
FAU - Sarkis, Elias
AU  - Sarkis E
FAU - Jain, Rakesh
AU  - Jain R
FAU - Adeyi, Ben
AU  - Adeyi B
FAU - Gao, Joseph
AU  - Gao J
FAU - Dirks, Bryan
AU  - Dirks B
FAU - Babcock, Thomas
AU  - Babcock T
FAU - Scheckner, Brian
AU  - Scheckner B
FAU - Richards, Cynthia
AU  - Richards C
FAU - Lasser, Robert
AU  - Lasser R
FAU - Findling, Robert L
AU  - Findling RL
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Central Nervous System Stimulants)
RN  - SJT761GEGS (Lisdexamfetamine Dimesylate)
RN  - TZ47U051FI (Dextroamphetamine)
SB  - IM
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy/physiopathology
MH  - Central Nervous System Stimulants/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Child
MH  - Dextroamphetamine/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Executive Function/*drug effects
MH  - Female
MH  - Humans
MH  - Lisdexamfetamine Dimesylate
MH  - Male
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Psychometrics
PMC - PMC3005278
EDAT- 2010/12/29 06:00
MHDA- 2011/04/13 06:00
PMCR- 2010/12/01
CRDT- 2010/12/29 06:00
PHST- 2010/12/29 06:00 [entrez]
PHST- 2010/12/29 06:00 [pubmed]
PHST- 2011/04/13 06:00 [medline]
PHST- 2010/12/01 00:00 [pmc-release]
AID - 10.1089/cap.2009.0110 [pii]
AID - 10.1089/cap.2009.0110 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2010 Dec;20(6):503-11. doi: 
      10.1089/cap.2009.0110.